Codiak BioSciences Email Format

Biotechnology ResearchMassachusetts, United States51-200 Employees

Codiak BioSciences is a clinical-stage biotechnology company focused on developing exosome-based therapeutics, a class of medicines built around natural intercellular transfer particles. The company uses a proprietary platform to design, engineer and produce engineered exosome candidates, aiming to expand the innate properties of exosomes for therapeutic use. Its pipeline targets a broad range of disease areas, including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases.

Headquartered in Cambridge, Massachusetts, the firm operates within the biotechnology research sector and pursues a diverse program across multiple disease areas. In June 2023, Evox Therapeutics announced the acquisition of Codiak’s engEx-AAV technology platform and related IP, representing a notable development noted in public sources.

Sign up for free to view info

Company overview Employee directory